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Objectives: Antiretroviral medications have extended the lives of persons living 
with HIV. As a result, the United States health care system will face challenges posed 
by an aging HIV+ population. This analysis describes the incidence and prevalence 
of HIV among individuals 65 years and older and characterizes the comorbid disease 
burden of these patients. MethOds: This retrospective analysis utilized Truven 
Health MarketScan® Commercial and Medicare Supplemental administrative health 
care claims. Prevalence and incidence were calculated for patients aged ≥ 65 for 
2005-2012. Patients with ≥ 1 non-diagnostic medical claim with an ICD-9-CM code 
for HIV (V08, 042) were considered to be HIV+. The first claim with an HIV diagnosis 
was referred to as the index date. Incident patients must have been enrolled for ≥ 6 
months prior to index date with no evidence of HIV diagnosis. Prevalent patients 
must have been enrolled for ≥ 3 months before and after a claim with HIV diagno-
sis within a given year to evaluate comorbid conditions. The earliest claim within 
the year meeting enrollment criteria was used. Denominators for prevalence and 
incidence were the number of individuals with ≥ 6 months of continuous enroll-
ment. Comorbidities were defined as ≥ 1 non-diagnostic claim with ICD-9-CM code 
for individual components of the Deyo Charlson Comorbidity Index. Results: 
The prevalence of HIV doubled from 2005 (22.5 cases per 100,000) to 2012 (46.9 
cases), while incidence decreased (2005= 11.2 per 100,000; 2012= 6.7). The mean age 
of prevalent cases decreased slightly from 71.8 years (SD 6.1) in 2005 to 69.9 (SD 
5.2) in 2012. The mean age of incident cases was 73.3 (SD 7.2). The most common 
comorbid conditions were chronic pulmonary disease (average proportion across 
years= 15.1%), diabetes (19.0%), and malignancy (14.7%). cOnclusiOns: Prevalence 
of HIV is increasing among those 65 and older and health systems must prepare to 
deliver care to older HIV+ patients with comorbid conditions.
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Objectives: The study purpose was to examine hepatitis C virus (HCV) prevalence, 
and geographic, age, gender and racial variations within the U.S. Medicaid popula-
tion. MethOds: HCV patients were identified from the Medicaid fee-for-service 
(FFS) population using International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes 070.41, 070.44, 070.51, 070.54 and V02.62 for 
this retrospective study (01JAN2008-31DEC2009). All patients were required to have 
2 years of continuous Medicaid FFS enrollment and no managed care enrollment 
in any month during the study period. HCV prevalence was analyzed by region, 
state, age, gender and race. Numbers and percentages were calculated to measure 
prevalence within the sample. Results: A total of 42,183 HCV patients (0.86%) 
were identified from the Medicaid FFS population in 2008 and 2009. Patients who 
were age 40-59 years were found to have the highest prevalence (2.61%), compared 
to those age 60+ (0.38%) and 0-39 years (0.27%). Prevalence analysis by race showed 
the following results: Black (1.28%), Hispanic (1.06%), White (0.74%), Asian (0.53%) 
and Native American (0.39%). In the study sample, male patients had a relatively 
higher prevalence (1.23%) than female patients (0.63%). HCV prevalence was also 
examined by U.S. state, with the highest HCV prevalence observed in Connecticut 
(2.59%), followed by Rhode Island (2.19%), New York (1.82%), Maryland (1.79%) and 
Missouri (1.71%). The highest prevalence rates were found in the Northeast (1.44%) 
compared to the Midwest (0.87%), South (0.52%) and West (0.49%). cOnclusiOns: 
Middle-aged patients have a higher probability of being diagnosed with HCV infec-
tion. Analysis by patient gender and race revealed that male and Black patients were 
at a higher risk for an HCV diagnosis. Additionally, patients residing in the Northeast 
were more likely to be diagnosed with an HCV infection.
PIN16
PrevaleNce Of HePaTITIS b vIruS INfecTION IN THe uNITed STaTeS 
medIcaId POPulaTION
Wang L.1, Xie L.2, Zhang J.1, Shrestha S.1, Wang Y.2, Kariburyo M.F.2, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
Objectives: To examine the geographic, age, gender and racial variations of hepa-
titis B virus (HBV) infection prevalence in the U.S. Medicaid population. MethOds: 
A retrospective study was conducted among the Medicaid fee-for-service (FFS) 
population in 2008 and 2009. Patients with an HBV diagnosis were identified using 
International Classification of Disease, Clinical Modification (ICD-9-CM) diagnosis 
codes 070.22, 070.23, 070.32, 070.33 and V02.61. Two years of continuous Medicaid 
FFS enrollment were required, and patients with managed care enrollment during 
the study period were excluded. HBV prevalence was stratified by region, state, age, 
gender and race. Descriptive statistics were calculated as number and percentage 
of patients in each category. Results: A total of 5,944 patients (0.12%) were diag-
nosed with HBV in 2008 and 2009. For HBV patients age 40-59 years, prevalence 
was the highest at 0.30%, followed by age group 60+ at 0.08%, and 0-39 at 0.05%. 
Prevalence stratified by race was examined, and Asian patients had the highest rate 
at 0.95%, compared to Black (0.17%), Hispanic (0.11%), Native American (0.09%) and 
White (0.08%) patients. Male patients were found to have a relative higher preva-
lence of HBV than female patients in the Medicaid population (0.19% vs. 0.08%). 
Geographic variation was analyzed, and the highest HBV prevalence was observed 
in Washington, DC (1.30%), followed by New York (0.35%), Minnesota (0.32%), Alaska 
(0.25%) and Connecticut (0.24%). The Northeastern U.S. region was found to have 
the highest prevalence (0.24%), compared to the Midwest (0.10%), South (0.06%) 
and West (0.06%). cOnclusiOns: Middle-aged patients had a higher probability 
Disease, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 088.81 from 
the Medicaid fee-for-service (FFS) population in 2008 and 2009. All patients were 
required to have 2 years of continuous Medicaid FFS enrollment and no man-
aged care enrollment for any month during the study period. Disease prevalence 
was stratified by region, state, age, gender and race for all patients. Numbers 
and percentages of patients in each category were calculated in the descriptive 
analysis to measure prevalence. Results: A total of 2,110 patients (0.04%) were 
diagnosed with Lyme disease in 2008 and 2009. Prevalence was the highest at 
0.08% for patients age 40-59 years, compared to those under age 40 (0.05%) and 
over age 60 (0.02%). Race variation analysis showed the highest Lyme disease 
prevalence in White patients (0.06%), followed by Asian (0.05%), Native American 
(0.03%), Hispanic (0.02%) and Black (0.01%). There was no gender variation in Lyme 
disease prevalence (0.04%) in the Medicaid FFS population. Prevalence, stratified 
by U.S. state, was also examined. The highest prevalence rates were found in 
Connecticut (0.28%), New Hampshire (0.27%), Rhode Island (0.21%), Maryland 
(0.18%) and Minnesota (0.12%). According to U.S. region, the Northeast (0.10%) 
had the highest prevalence rate, followed by the Midwest (0.03%), South (0.02%) 
and West (0.00%). cOnclusiOns: Middle-aged patients were shown to have a 
higher probability for a Lyme disease diagnosis. Stratified by race, White patients 
were more likely to be diagnosed with Lyme disease compared to all other races. 
There is also statistical evidence that patients located in the Northeastern U.S. 
region have a higher risk for a Lyme disease diagnosis.
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Objectives: Prior studies have demonstrated increasing Clostridium difficile infec-
tions (CDI) in United States (U.S.) hospitals; however, it is unknown if regional 
or seasonal differences exist. This study identifies regional and seasonal varia-
tions in CDI incidence and mortality among hospitalized adults over a ten-year 
period. MethOds: This was a retrospective analysis of the U.S. National Hospital 
Discharge Surveys from 2001 to 2010. Eligible cases included adults ≥ 18 years of 
age with an ICD-9-CM diagnosis code for CDI (008.45). Data weights were used to 
derive national estimates. Mortality and CDI incidence were presented descrip-
tively. CDI incidence rates were calculated as CDI discharges per 1,000 total adult 
discharges. Regions included the Northeast, Midwest, South, and West as defined 
by the U.S. Census Bureau. Seasons included: Winter (December-February), Spring 
(March-May), Summer (June-August), and Fall (September-November). Results: 
These data represent 2.2 million adult CDI discharges. CDI incidence was highest in 
the Northeast (9.2 CDI discharges/1,000 total discharges), followed by the Midwest 
(7.4 CDI discharges/1,000 total discharges), South (5.9 CDI discharges/1,000 total 
discharges), and West (5.7 CDI discharges/1,000 total discharges). Rates increased 
in all regions through 2008. Although, rates declined in the Northeast, Midwest, 
and West since 2008, rates in the South continued to increase until study end. CDI 
incidence was highest in the Spring (7.2 CDI discharges/1,000 total discharges), 
followed by the Summer (6.9 CDI discharges/1,000 total discharges), Winter (6.8 
CDI discharges/1,000 total discharges), and Fall (6.6 CDI discharges/1,000 total dis-
charges). Rates increased in all seasons over the study period, but have declined in 
the Fall since 2008. Mortality among CDI patients was highest in the Midwest (7.5%) 
and during the Winter (8.5%). cOnclusiOns: CDI increased for all regions over the 
study period, and was highest in the Northeast. Peak CDI incidence occurred in the 
Spring, but mortality was highest in the Winter.
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Objectives: Post-Treatment Lyme Disease Syndrome (PTLDS) refers to persistent 
musculoskeletal and neurological symptoms after antibiotic treatment for Lyme 
disease (LD). This study’s objectives were to examine real-world PTLDS incidence 
and treatment patterns, and assess the utility of administrative claims data to 
measure PTLDS outcomes. MethOds: Patients with an LD diagnosis (ICD-9 088.81) 
between 2010-2012 and ≥ 14 days supply of first-line oral antibiotics (amoxicillin, 
doxycycline, cefuroxime axetil) were identified using Truven Health MarketScan® 
Treatment Pathways. PTLDS was measured from inpatient/outpatient claims 6-12 
months after LD diagnosis (index), using relevant symptoms, signs and ill-defined 
condition codes (ICD-9 780-799) and other related codes because PTLDS does not 
have a specific code. Treatments were measured from outpatient pharmacy claims 
and procedure codes. Results: Patients (N= 13,436) were 53% male, with a mean age 
of 41. Most (73%) resided in New England and the Mid Atlantic. PTLDS symptoms of 
headache, stiff neck, sleep disturbance and memory/cognitive problems were coded 
on claims 6-12 months post-index for 8% of patients. A broader constellation of 
PTLDS symptoms including paresthesias, visual/hearing disturbances, lightheaded-
ness and depression was coded for 14%. Seventeen percent had claims indicative of 
musculoskeletal symptoms. Median first-line antibiotic days supply over 12 months 
was 24 days. Five percent of patients had > 90 days supply over 12 months. Three 
percent received parenteral antibiotics. Patients with PTLDS-related claims had 
longer antibiotic days supply than patients without PTLDS-related claims (p< 0.001). 
Trends were similar for adults and children, but PTLDS incidence and average anti-
biotic days supply were higher among adults. cOnclusiOns: PTLDS rates in this 
study correspond with previous research, suggesting PTLDS case identification in 
claims data may be feasible. Experts disagree about long-term antibiotic treatment 
for PTLDS; only a small proportion of patients in this study received this treatment. 
Future research is needed to help resolve controversies surrounding appropriate 
PTLDS treatment.
